april
world
health
organ
establish
prioriti
list
pathogen
includ
middl
east
respiratori
syndrom
mer
sever
acut
respiratori
syndrom
sar
diseas
x
diseas
epidem
pandem
potenti
caus
unknown
fig
late
decemb
outbreak
pneumonia
unknown
etiolog
wuhan
china
consid
first
diseas
x
follow
announc
shortli
thereaft
novel
coronaviru
denot
identifi
pathogen
caus
coronaviru
diseas
sequenc
ident
sarscov
bat
coronaviru
renam
coronavirida
studi
group
csg
intern
committe
taxonomi
virus
ictv
interim
renam
common
viru
name
group
virologist
februari
total
confirm
case
includ
death
report
china
pose
seriou
threat
global
public
health
thu
call
prompt
develop
specif
anticoronaviru
therapeut
prophylact
treatment
prevent
coronavirus
cov
largest
rna
virus
identifi
far
belong
coronavirida
famili
divid
genera
divid
b
c
lineag
seven
cov
infect
human
hcov
includ
lineag
sarscov
lineag
b
coronavirus
merscov
lineag
develop
specif
fusion
inhibitor
essenti
studi
fusion
capac
compar
sarscov
particularli
sarscov
sequenc
ident
spike
protein
subunit
mediat
membran
fusion
process
subunit
util
human
angiotensinconvert
enzym
receptor
infect
human
importantli
affin
receptorbind
domain
rbd
subunit
protein
higher
may
contribut
higher
infect
transmiss
compar
sarscov
howev
unclear
whether
mediat
membran
fusion
manner
exce
capac
sarscov
bind
rbd
subunit
protein
virion
receptor
target
cell
heptad
repeat
domain
subunit
protein
interact
form
sixhelix
bundl
fusion
core
bring
viral
cellular
membran
close
proxim
fusion
therefor
fusion
core
structur
sarscov
protein
also
compar
order
investig
structur
basi
membran
fusion
mediat
protein
thu
set
stage
ration
design
coronaviru
fusion
inhibitor
previou
studi
design
pancoronaviru
fusion
inhibitor
target
domain
hcov
protein
prove
effect
inhibit
infect
hcov
includ
sarscov
merscov
sarsrel
cov
sarsrcov
intranas
applic
peptid
either
pre
postchalleng
coronaviru
treat
mice
protect
merscov
infect
suggest
peptid
prophylact
therapeut
potenti
inde
recent
studi
shown
peptid
effect
proteinmedi
membran
fusion
psv
infect
dosedepend
studi
shown
exhibit
much
higher
capac
membran
fusion
sarscov
suggest
fusion
machineri
import
target
develop
coronaviru
fusion
inhibitor
solv
xray
crystal
structur
core
identifi
sever
mutat
amino
acid
residu
domain
respons
enhanc
interact
domain
conjug
cholesterol
molecul
peptid
found
one
lipopeptid
exhibit
highli
potent
inhibitori
activ
smediat
membran
fusion
psv
infect
potent
peptid
respect
also
highli
effect
vitro
vivo
infect
live
hcov
merscov
suggest
potenti
develop
pancov
fusion
inhibitorbas
therapeut
prophylact
treatment
prevent
infect
current
circul
merscov
well
futur
reemerg
sarscov
emerg
sarsrcov
gisaid
platform
http
platformgisaidorg
obtain
fulllength
aminoacid
sequenc
betacov
protein
genbank
align
sarscov
slcov
protein
locat
function
domain
protein
contain
subunit
subunit
cleavag
site
subunit
locat
within
ntermin
amino
acid
protein
contain
ntermin
domain
ntd
receptor
bind
domain
rbd
receptor
bind
motif
rbm
subunit
contain
fusion
peptid
fp
heptad
repeat
heptad
repeat
transmembran
domain
tm
cytoplasm
domain
cp
fig
recent
biophys
structur
evid
show
protein
bind
higher
affin
sarscov
protein
suggest
higher
infect
new
unlik
coronavirus
protein
harbor
special
furinrecogniz
site
indic
protein
might
possess
uniqu
infecti
properti
inde
live
infect
found
typic
syncytium
phenomenon
natur
form
infect
cell
rare
report
sarscov
infect
fig
explor
special
characterist
infect
clone
gene
paaviresgfp
vector
establish
smediat
fusion
system
use
cell
express
protein
egfp
effector
cell
cell
express
human
receptor
target
cell
fig
supplementari
inform
fig
effector
cell
target
cell
cocultur
h
fuse
cell
show
least
larger
size
normal
cell
multipl
nuclei
cell
observ
group
sarscov
group
coincub
h
hundr
target
cell
fuse
togeth
one
big
syncytium
contain
multipl
nuclei
fig
anoth
h
later
syncytium
grew
bigger
could
easili
observ
light
fluoresc
microscopi
fig
similar
result
observ
fusion
cell
cell
natur
express
human
receptor
cell
surfac
syncytium
obvious
form
coincub
h
similar
syncytium
form
live
cell
fig
f
contrari
sarscov
protein
lack
abil
mediat
fusion
condit
fig
base
requir
presenc
exogen
trypsin
complet
membran
fusion
previou
studi
therefor
compar
sarscov
protein
show
much
effici
mediat
viral
surfacefus
entri
target
meanwhil
fusion
observ
cell
without
sexpress
cell
without
fig
supplementari
inform
fig
confirm
sreceptor
engag
necessari
smediat
viral
fusion
entri
previous
identifi
form
domain
subunit
play
import
role
membran
fusion
process
mediat
merscov
sarscov
similarli
recent
studi
suggest
subunit
also
interact
form
coiledcoil
complex
support
membran
fusion
viral
fig
supplementari
inform
fig
howev
specif
bind
characterist
remain
explor
understand
structur
basi
interact
region
fusion
protein
contain
major
part
residu
residu
flexibl
linker
sggrgg
construct
crystallograph
studi
crystal
structur
show
canon
structur
rodlik
shape
length
diamet
fig
three
domain
form
parallel
trimer
coiledcoil
center
around
three
domain
entwin
antiparallel
manner
interact
two
domain
predominantli
hydrophob
forc
pair
two
adjac
helic
form
deep
hydrophob
groov
provid
bind
site
hydrophob
residu
domain
includ
fig
hydrophob
interact
mainli
locat
helic
fusion
core
region
discuss
later
overal
structur
similar
hcov
rootmeansquar
deviat
rmsd
sarscov
merscov
atom
fig
find
suggest
overal
conform
import
highli
conserv
compon
danger
coronavirus
compar
common
coronavirus
caus
mild
respiratori
diseas
similar
overal
structur
except
differ
length
helix
domain
form
longer
bend
helix
interact
trimer
core
fig
relationship
structur
differ
pathogen
hcov
remain
elucid
accord
sequenc
align
subunit
sarscov
highli
conserv
overal
homolog
domain
respect
insid
fusion
core
region
domain
differ
residu
fig
may
contribut
enhanc
interact
stabil
conform
reveal
crystallograph
analysi
compar
sarscov
signific
differ
observ
sarslik
virus
shown
fig
sarscov
could
bind
salt
bridg
distanc
howev
lysser
replac
bind
strong
hydrogen
bond
distanc
sarscov
domain
bind
domain
howev
qk
replac
new
viru
domain
bind
carbonyl
oxygen
salt
bridg
distanc
fig
sarscov
domain
bind
domain
weak
salt
bridg
distanc
mutat
bind
domain
salt
bridg
distanc
fig
sarscov
bind
salt
bridg
distanc
involv
interact
howev
mutat
could
bind
domain
hydrogen
bond
distanc
could
also
bind
salt
bridg
distanc
fig
result
suggest
multipl
replac
domain
emerg
viru
could
enhanc
interact
domain
stabil
structur
may
lead
increas
infect
viru
previous
found
peptid
could
disturb
viral
format
effect
inhibit
psv
infect
howev
potent
stabil
structur
might
reduc
antivir
efficaci
recent
numer
report
shown
lipid
strategi
effect
improv
antivir
activ
fusion
inhibitori
peptid
peptid
antinipah
viru
order
improv
inhibitori
activ
cholesterol
chol
palmit
acid
palm
coval
attach
cterminu
sequenc
help
flexibl
polyethylen
glycol
peg
spacer
correspond
lipopeptid
construct
respect
fig
could
complet
inhibit
mediat
fusion
concentr
fig
inhibitori
activ
mean
inhibitori
concentr
valu
nm
nm
respect
fig
meanwhil
peptid
show
inhibitori
activ
concentr
fig
result
strongli
suggest
lipid
promis
strategi
improv
fusioninhibitori
activ
infect
especi
cholesterolmodif
basi
structur
seri
cholesteryl
multipl
linker
construct
glycineserinebas
linker
ie
gsg
pegbas
spacer
employ
cholesterol
moieti
fig
compar
show
similar
inhibitori
activ
strikingli
peptid
acid
linker
gsg
spacer
exhibit
potenc
noteworthi
chang
gsg
longer
acid
linker
gsgsg
significantli
increas
inhibitori
potenc
hybrid
molecul
valu
nm
potent
find
indic
linker
length
signific
effect
overal
activ
lipopeptid
comparison
increas
pegbas
arm
length
show
inhibitor
potenc
slightli
decreas
fusion
assay
fig
data
suggest
linker
optim
bridg
part
conjug
similarli
show
potent
inhibitori
activ
psv
infect
valu
nm
provid
stronger
activ
nm
fig
previous
demonstr
could
effect
inhibit
diverg
hcov
infect
target
domain
includ
systemat
evalu
broadspectrum
surfacefus
inhibitori
activ
fusion
mediat
protein
diverg
coronavirus
includ
sarscov
merscov
among
sarscov
closest
rel
proteinmedi
fusion
could
effect
inhibit
nm
activ
nm
fig
similarli
show
extrem
potent
fusioninhibitori
activ
merss
fusion
nm
nm
potent
compar
respect
indic
could
potent
broadli
inhibit
proteinmedi
fusion
variou
fig
c
also
effect
block
fusion
process
mediat
protein
nm
nm
respect
show
inhibitori
activ
rang
nm
fig
e
moreov
potenti
human
infect
slcov
includ
fusion
process
mediat
protein
could
also
significantli
prevent
rang
nm
well
rang
nm
fig
control
peptid
show
inhibitori
activ
concentr
coronaviru
fusion
assay
fig
also
assess
antivir
activ
psv
infect
diverg
coronavirus
expect
show
much
potent
activ
rang
nm
sarscov
merscov
infect
nm
nm
nm
respect
fig
also
effect
block
psv
infect
includ
nm
nm
respect
activ
rang
nm
fig
similarli
cholesteryl
modif
linker
inhibitori
activ
could
significantli
increas
psv
infect
slcov
includ
show
potent
inhibitori
activ
nm
nm
respect
potent
fig
assess
inhibitori
activ
live
hcov
infect
includ
merscov
importantli
effect
block
infect
cellular
level
dosedepend
manner
nm
activ
nm
fig
consist
result
fusion
assay
psv
infect
assay
mediat
protein
similarli
also
show
potent
antivir
activ
merscov
infect
nm
nm
nm
nm
respect
potent
respect
fig
next
assess
cytotox
variou
target
cell
found
half
cytotox
concentr
beyond
highest
detect
concentr
supplementari
inform
fig
therefor
select
index
si
suggest
promis
fusion
inhibitor
littl
even
toxic
effect
vitro
explor
potent
antivir
mechan
found
complex
harbor
higher
stabil
increas
tm
valu
complex
form
supplementari
inform
fig
result
suggest
increas
antivir
activ
relat
increas
bind
affin
detail
interact
requir
studi
recent
rapidli
spread
human
transmit
respiratori
tract
use
infect
mous
model
investig
potenti
prophylact
effect
clinic
applic
via
intranas
administr
rout
fig
g
mous
model
treat
newborn
mice
singl
dose
mgkg
h
h
h
h
challeng
tissu
cultur
infecti
dose
start
day
postinfect
dpi
bodi
weight
mice
viral
control
group
decreas
significantli
along
mortal
fig
g
final
surviv
rate
mice
group
respect
fig
g
contrast
singl
dose
mgkg
via
nasal
administr
exhibit
promis
prophylact
effect
h
h
group
wherea
mice
h
group
eventu
die
similarli
mice
viral
control
group
supplementari
inform
fig
result
suggest
better
stabil
antivir
activ
prolong
halflif
airway
environ
compar
test
therapeut
effect
h
group
h
group
infect
fig
group
group
mice
show
surviv
rate
respect
suggest
harbor
good
therapeut
effect
short
period
infect
possibl
result
establish
infect
mous
brain
get
blood
brain
barrier
via
nasal
shown
supplementari
inform
fig
high
viral
titer
detect
brain
mice
group
mice
group
detect
brain
tissu
mice
group
moder
level
viral
titer
detect
brain
tissu
one
mice
group
supplementari
inform
fig
b
similar
viral
control
mice
mice
group
exhibit
similar
histopatholog
chang
brain
tissu
includ
vacuol
degener
infiltr
howev
brain
tissu
mice
group
well
normal
control
group
show
appar
histopatholog
chang
supplementari
inform
fig
past
year
highli
infecti
pathogen
emerg
increasingli
sarscov
merscov
propos
diseas
x
blueprint
prioriti
diseas
new
unknown
pathogen
may
caus
epidem
pandem
futur
call
develop
effect
safe
vaccin
antivir
prevent
treat
diseas
x
inde
end
outbreak
wuhan
pneumonia
unknown
etiolog
agent
first
diseas
x
follow
announc
report
shortli
thereaft
novel
coronaviru
also
known
identifi
etiolog
wuhan
pneumonia
ie
design
unlik
sarscov
live
cell
found
form
typic
syncytium
suggest
may
mainli
util
plasma
membran
fusion
pathway
enter
replic
insid
host
cell
consist
fusion
system
protein
could
effect
mediat
format
syncytium
effector
cell
target
cell
absenc
exogen
proteolyt
enzym
eg
trypsin
sarscov
protein
could
actual
plasma
membran
fusion
pathway
effici
endosom
membran
fusion
pathway
virus
latter
prone
activ
host
cell
antivir
gener
coronavirus
lack
furinrecognit
site
protein
uncleav
nativ
state
exampl
sarscov
enter
cell
mainli
via
endosom
membran
fusion
pathway
protein
cleav
endosom
cathepsin
l
induc
furinrecognit
site
could
significantli
increas
capac
sarscov
protein
mediat
cellular
membran
surfac
interestingli
harbor
cleavag
site
protein
specif
role
proteinmedi
membran
fusion
viral
lifecycl
remain
explor
supplementari
inform
fig
recent
report
suggest
mainli
use
plasma
membran
fusion
mean
inhibitor
might
constitut
option
block
fusion
entri
host
structur
form
region
subunit
hcov
play
key
role
viral
membran
fusion
process
make
one
import
target
drug
design
previou
studi
found
could
form
stabl
coiledcoil
complex
detail
conform
remain
unknown
accord
xray
crystallograph
analysi
complex
form
fig
typic
fusion
core
structur
similar
sarscov
merscov
although
amino
acid
sequenc
domain
sarscov
fulli
ident
multipl
residu
differ
occur
domain
howev
instead
weaken
interact
unilater
differ
seem
form
new
interact
region
enhanc
exist
one
region
fig
sarscov
replac
new
strong
hydrogen
bond
form
distanc
form
new
interact
distanc
wherea
correspond
posit
sarscov
interact
two
region
bind
bind
sarscov
enhanc
result
suggest
new
hcov
evolv
improv
bind
affin
domain
may
acceler
viral
membran
fusion
process
enhanc
viral
infect
transmiss
recent
studi
also
found
bind
affin
receptor
host
cell
rbd
protein
higher
sarscov
may
also
associ
increas
infect
transmiss
conjug
cholesterol
viral
entri
inhibitor
prove
effect
strategi
enhanc
antivir
activ
peptid
howev
mechan
enhanc
especi
role
cholesterol
group
ctermin
tail
entri
inhibitor
still
unclear
possibl
cholesterol
group
could
anchor
target
membran
facilit
bind
inhibitor
target
howev
notic
bind
affin
significantli
enhanc
peptid
alon
suggest
cholesterol
group
may
involv
bind
directli
supplementari
inform
fig
therefor
use
structur
simul
dock
method
predict
possibl
model
bind
supplementari
inform
fig
model
peptid
anchor
one
three
hydrophob
groov
trimer
via
moieti
also
anchor
anoth
adjac
hydrophob
groov
trimer
via
cholesterol
moieti
cholesterol
group
may
bind
hydrophob
interact
sever
hydrogen
bond
may
form
helic
region
intermedi
linker
peptid
enough
connect
two
moieti
two
bind
target
admittedli
exact
mechan
structur
need
studi
futur
past
decad
viral
domain
prove
import
target
develop
viral
fusion
entri
inhibitor
earli
outbreak
mer
quickli
solv
fusion
core
structur
form
merscov
protein
domain
design
fusion
inhibitori
peptid
prove
highli
effect
block
spike
proteinmedi
membran
fusion
inhibit
vitro
merscov
result
anim
experi
show
intranas
applic
peptid
could
effect
protect
mice
merscov
infect
reduct
viru
titer
lung
howev
merscov
peptid
could
inhibit
sarscov
infect
suggest
peptid
lack
crossinhibitori
activ
sarscov
bat
sarsrcov
well
prepar
combat
emerg
coronavirus
epidem
pandem
potenti
design
synthes
first
pancoronaviru
fusion
inhibitor
found
exhibit
potent
inhibitori
activ
hcov
test
includ
sarscov
marscov
well
bat
sarsrcov
expect
recent
shown
also
effect
inhibit
infect
novel
optim
peptid
hope
improv
fusion
inhibitori
activ
inde
found
one
modifi
peptid
potent
proteinmedi
membran
fusion
psv
infect
respect
also
show
broadspectrum
inhibitori
activ
infect
sarscov
merscov
hcov
show
prolong
signific
prophylact
effect
infect
mous
model
suggest
may
also
use
inhibitor
infect
vivo
consist
shown
typic
neurotrop
viru
mous
model
quickli
enter
establish
infect
mous
brain
tissu
lead
rel
weak
therapeut
effect
via
intranas
administr
howev
mainli
infect
caus
sever
patholog
chang
human
lung
therefor
administ
intranas
expect
good
therapeut
potenti
infect
current
specif
anticov
therapeut
prophylact
use
clinic
treatment
prevent
infect
number
nonspecif
antivir
drug
includ
ifn
lopinavirritonavir
hiv
proteas
inhibitor
chloroquin
favipiravir
remdesivir
use
clinic
china
treat
vivo
efficaci
still
requir
confirm
potenti
use
treatment
infect
coronavirus
emerg
coronavirus
futur
unclear
compar
clinic
use
nonspecif
antivir
drug
advantag
treatment
prevent
infect
first
sequenc
target
domain
subunit
protein
highli
conserv
therefor
possess
high
genet
barrier
resist
easili
induc
drugresist
mutat
second
use
intranas
formul
prevent
coronaviru
infect
small
bottl
carri
easili
person
close
contact
infect
patient
highrisk
popul
third
use
inhal
formul
treatment
patient
reduc
viral
load
lung
thu
attenu
acut
lung
injuri
caus
viral
infect
reduc
chanc
spread
virion
close
contact
person
inhal
equip
use
home
hotel
room
reduc
expens
stay
hospit
fourth
expect
safe
human
use
local
system
peptid
drug
gener
safer
chemic
drug
fifth
broadspectrum
anticoronaviru
activ
use
treatment
prevent
infect
also
hcov
sixth
recent
genom
found
domain
among
report
genom
show
ident
supplementari
inform
fig
indic
high
conserv
target
meantim
deriv
peptid
much
larger
interfac
domain
make
resist
viral
mutat
therefor
show
except
promis
develop
first
pancov
fusion
inhibitorbas
antivir
therapeut
prophylact
treatment
prevent
infect
current
circul
merscov
futur
reemerg
sarscov
emerg
sarsrcov
human
primari
embryon
kidney
cell
line
vero
rd
origin
cell
obtain
american
type
cultur
collect
atcc
human
hepatoma
cell
cell
bank
chines
academi
scienc
shanghai
china
cell
stabli
express
human
cell
kindli
provid
ld
cell
line
maintain
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
carlsbad
ca
usa
contain
uml
penicillin
mgml
streptomycin
heatinactiv
fetal
calf
serum
fc
gibco
patientderiv
isol
wuhan
institut
origin
provid
chuan
qin
beij
key
laboratori
anim
model
emerg
reemerg
infecti
diseas
atcc
strain
human
coronaviru
well
human
coronaviru
amsterdam
strain
strain
amplifi
cell
respect
peptid
synthes
chao
wang
beij
institut
pharmacolog
toxicolog
sequenc
sldqinvtfldleyemkkleeaikkleesyidlkel
lkvllyeefklleslimeileyqkdsdikenaedtk
report
previou
envelopeexpress
plasmid
sarss
merss
bat
sarslik
cov
plasmid
paaviresegfp
encod
egfp
well
luciferas
report
vector
maintain
laboratori
establish
detect
sever
fusion
assay
previous
brief
cell
test
coronavirus
cell
test
use
target
cell
prepar
effector
cell
express
protein
coronaviru
cell
transfect
one
protein
express
vector
includ
empti
plasmid
paaviresegfp
sarscov
slcov
smediat
fusion
assay
effector
cell
target
cell
cocultur
dmem
contain
trypsin
ngml
h
merscov
smediat
fusion
assay
effector
cell
target
cell
cocultur
dmem
without
trypsin
fb
h
incub
five
field
randomli
select
well
count
number
fuse
unfus
cell
invert
fluoresc
microscop
nikon
eclips
ti
inhibitori
activ
peptid
hcov
smediat
fusion
assess
previous
briefli
total
cellswel
target
cell
incub
h
afterward
cellswel
effector
cell
ad
presenc
absenc
peptid
indic
concentr
h
cell
phosphatebuff
salin
pb
use
neg
control
fusion
rate
calcul
observ
fuse
unfus
cell
use
fluoresc
microscopi
cell
cotransfect
luciferas
reporterexpress
backbon
encod
cov
protein
use
vigofect
vigor
biotechnolog
beij
china
pseudotyp
particl
effici
releas
supernat
supernat
harvest
h
posttransfect
centrifug
g
min
frozen
detect
inhibitori
activ
peptid
infect
coronaviru
psv
target
cell
sarscov
slcov
rd
cell
cov
plate
densiti
cell
per
well
plate
one
day
prior
psv
mix
equal
volum
peptid
seri
dilut
pb
min
mixtur
transfer
cell
medium
chang
h
incub
continu
h
luciferas
activ
analyz
luciferas
assay
system
promega
madison
wi
usa
inhibit
assay
live
merscov
perform
biosafeti
level
facil
wuhan
research
institut
beij
key
laboratori
anim
model
emerg
reemerg
infecti
diseas
inhibit
activ
peptid
merscov
determin
plaqu
reduct
assay
peptid
differ
dilut
concentr
mix
min
ad
monolay
cell
adsorpt
supernat
remov
methyl
cellulos
overlaid
cell
h
plate
fix
stain
plaqu
count
fix
paraformaldehyd
stain
crystal
violet
test
effect
peptid
replic
viru
mix
equal
volum
peptid
incub
h
afterward
mixtur
ad
rd
cell
respect
cell
count
dojindo
kumamoto
kyushu
japan
assay
appli
determin
cytopath
effect
peptid
peptid
mixtur
dissolv
pb
prepar
solut
final
concentr
min
measur
circular
dichroism
scan
wavelength
rang
nm
thermal
denatur
detect
start
nm
thermal
gradient
detect
newborn
mice
bred
pregnant
mice
purchas
anim
center
fudan
univers
relat
experi
carri
strict
accord
institut
regul
approv
number
approv
date
februari
group
mice
test
protect
effect
peptid
hcovinfect
mice
mgkg
mgkg
hbc
phosphatebuff
salin
pb
solut
administ
intranas
h
challeng
h
challeng
mice
challeng
intranas
hcov
dose
viral
control
group
volum
hbc
pb
administ
intranas
group
six
mice
randomli
select
euthanasia
day
infect
five
mice
collect
assess
viral
titer
mous
brain
one
mous
brain
histolog
examin
bodi
weight
surviv
remain
six
mice
group
monitor
cytotox
peptid
cell
rd
cell
test
use
cell
count
briefli
cell
type
seed
well
microtit
plate
per
well
incub
h
replac
medium
dmed
contain
grade
concentr
cultur
day
solut
per
well
ad
follow
addit
incub
h
absorb
measur
nm
code
sequenc
residu
residu
domain
subunit
tandem
link
though
linker
sggrgg
result
sequenc
encod
fuse
protein
clone
modifi
vector
contain
tag
upstream
multipl
clone
site
recombin
construct
express
escherichia
coli
cell
grown
lysogeni
broth
lb
media
supplement
kanamycin
induc
mm
iptg
h
overnight
cell
harvest
centrifug
g
min
lyse
highpressur
homogen
twice
resuspens
buffer
contain
mm
ph
mm
nacl
fusion
protein
isol
niaffin
chromatographi
sumo
tag
remov
enzym
ww
cleavag
protein
concentr
gelfilt
superdex
ge
healthcar
column
peak
fraction
contain
trimer
pool
concentr
mgml
centrifug
emd
millipor
crystal
obtain
day
use
hang
drop
vapor
diffus
method
mix
equal
volum
protein
solut
mgml
reservoir
solut
mm
zinc
acet
me
ph
crystal
flashfrozen
transfer
liquid
nitrogen
data
collect
inhous
institut
biophys
chines
academi
scienc
xray
sourc
micromax
gener
rigaku
japan
combin
varimax
hr
optic
rigaku
japan
crystal
k
diffract
resolut
wavelength
nativ
set
xray
diffract
data
collect
raxi
iv
detector
rigaku
japan
exposur
time
min
per
imag
index
process
use
space
group
collect
dataset
molecular
replac
perform
solv
phase
problem
use
sarscov
protein
core
structur
pdb
code
search
model
final
model
manual
adjust
coot
refin
data
collect
statist
refin
statist
given
tabl
coordin
deposit
rcsb
protein
data
bank
pdb
code
interact
model
peptid
domain
predict
swissmodel
use
refer
moieti
autodock
cholesterol
moieti
supplementari
inform
fig
surviv
rate
mice
analyz
graphpad
prism
softwar
calcusyn
softwar
kindli
provid
tc
chou
percent
inhibit
valu
calcul
base
